Price
No data yet.
Social Signal Score
Analyst Ratings
5 analystsRevenue
$19.42M+250.15%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- James L. Cunniff
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 196
- Beta
- 0.46
- Country
- US
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 14.62
Financials
Revenue
$19.42M+250.1%Net Income
$3.40M+1679.0%EBITDA
$4.10M+761.9%Free Cash Flow
$2.73MEPS (diluted)
$0.39+1850.0%Shares Outstanding (diluted)
8.69M+2.8%Operating Expenses
$11.46MCash & Debt
$20.45MReturn of Capital
$0.00Revenue by Segment (annual)
$1.67MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $73.78M | $11.30M | $1.37 |
| 2025 | $64.00M | $7.54M | $0.90 |
| 2024 | $54.72M | $5.15M | $0.60 |
| 2023 | $48.07M | $3.17M | $0.37 |
| 2022 | $41.66M | $2.31M | $0.27 |
| 2021 | $35.76M | $2.36M | $0.28 |
| 2020 | $32.47M | $4.16M | $0.50 |
| 2019 | $31.30M | $1.98M | $0.24 |
| 2018 | $28.31M | $1.83M | $0.23 |
| 2017 | $25.86M | $2.23M | $0.27 |
| 2016 | $22.99M | $2.21M | $0.27 |
| 2015 | $19.41M | $1.09M | $0.13 |
| 2014 | $15.49M | $-1.29M | $-0.16 |
| 2013 | $15.10M | $-1.33M | $-0.16 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $2.01
- Implied price
- $62.27
- Return from $28.27
- 17.1% a year
To earn 15.0% a year on these assumptions you'd need to buy at $30.96 — today's price is already 8.7% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 21 | 26 | 31 | 36 | 41 |
|---|---|---|---|---|---|
| -2.0% | -1.7% | 2.6% | 6.3% | 9.5% | 12.4% |
| 3.0% | 3.3% | 7.8% | 11.7% | 15.1% | 18.1% |
| 8.0% | 8.3% | 13.1% | 17.1% | 20.7% | 23.8% |
| 13.0% | 13.3% | 18.3% | 22.5% | 26.3% | 29.6% |
| 18.0% | 18.4% | 23.5% | 28.0% | 31.8% | 35.3% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
50-70.59%Social Signal Score
Mentions (4)
- Newsbusinesswire.com·30d ago·Neutral
Electromed, Inc. to Participate in the H.C. Wainwright 28th Annual Global Investment Conference and LD Micro 20th Annual Main Event NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. to Participate in the H.C. Wainwright 28th Annual Global Investment Conference and LD Micro 20th Annual Main Event.
View source ↗ - Newsseekingalpha.com·42d ago·Positive
Electromed: Contrarian 'Buy' With SmartVest Electromed's direct-to-patient model, broad payer coverage, and disciplined sales execution support durable SmartVest growth. The bronchiectasis market remains substantially underpenetrated, leaving a long runway for greater HFCWO adoption. Hospital revenue is volatile, but the channel remains small and full-year hospital sales still increased.
View source ↗ - Newsseekingalpha.com·45d ago·Positive
Electromed, Inc. (ELMD) Q4 2026 Earnings Call Transcript Electromed, Inc. (ELMD) Q4 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·45d ago·Positive
Electromed, Inc. (ELMD) Surpasses Q4 Earnings Estimates Electromed, Inc. (ELMD) came out with quarterly earnings of $0.39 per share, beating the Zacks Consensus Estimate of $0.32 per share. This compares to earnings of $0.25 per share a year ago.
View source ↗
Earnings
Wed, Nov 11(in 5 weeks)
Consensus estimate $0.26 per share
Typical surprise +18.5% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 25$0.39 vs $0.32beat
- Tue, May 12$0.35 vs $0.26beat
- Tue, Feb 10$0.32 vs $0.27beat
- Wed, Nov 12$0.25 vs $0.22beat
- Tue, Aug 26$0.25 vs $0.22beat
- Tue, May 13$0.21 vs $0.20beat
Estimates and results for ELMD via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ELMD officers and directors.
- Bought
- $450k
- Sold
- $16.5m
3 trades
44 trades
- Cunniff James L.sold
- Cunniff James L.sold
- Cunniff James L.sold
- Nagel Bradley M.sold
- Nagel Bradley M.sold
- Skarvan Kathleensold
- Skarvan Kathleensold
- Skarvan Kathleensold
53 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ELMD.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.